drugset / Trial / NCT04480593

The Use of Brazilian Green Propolis Extract (EPP-AF) in Patients Affected by COVID-19.

NCT04480593 ↗

RandomizedParallel-groupSingle-blindTreatment

Summary

The COVID-19 pandemic is of grave concern due its impact on human health and on the economy. Propolis, a natural resin produced by bees from plant materials, has anti-inflammatory, immunomodulatory, anti-oxidant properties, and various aspects of the SARS-CoV-2 infection mechanism are potential targets for propolis compounds. Propolis components have inhibitory effects on the ACE2, TMPRSS2 and PAK1 signaling pathways; in addition, antiviral activity has been proven in vitro and in vivo. This is a pilot randomized study that aims to assess the impact of using Brazilian green propolis extract against the deleterious effects of the new coronavirus.

Timeline

Start
2020-06-02
Primary completion
2020-08-30
Completion
2020-08-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Brazilian Green Propolis Extract Traditional medicine (herbal / TCM) 400 mg Oral
Subject Brazilian Green Propolis Extract Traditional medicine (herbal / TCM) 800 mg Oral

Indications